A novel pre-clinical antibacterial pipeline database
| Autor: | Richard A. Alm, Peter Beyer, Sarah Paulin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Databases Pharmaceutical Drug Evaluation Preclinical computer.software_genre Pathology and Laboratory Medicine Global Health 0302 clinical medicine Antibiotics Medicine and Health Sciences Public and Occupational Health Multidisciplinary Collection Review Database Antimicrobials Organic Compounds Drugs Vaccination and Immunization Bacterial Pathogens Anti-Bacterial Agents Actinobacteria Identification (information) Chemistry Incentive Medical Microbiology 030220 oncology & carcinogenesis Physical Sciences Medicine Engineering and Technology Pathogens Biotechnology Science Immunology Bioengineering Microbiology 03 medical and health sciences Microbial Control Microbial Pathogens Upstream (petroleum industry) Pharmacology Bacteria Antibacterial Therapy Organic Chemistry Chemical Compounds Organisms Biology and Life Sciences Market dynamics Pipeline (software) 030104 developmental biology Antibacterial therapy Small Molecules Antibiotic Resistance Push and pull Antibacterials Business Antimicrobial Resistance Preventive Medicine computer Mycobacterium Tuberculosis |
| Zdroj: | PLoS ONE PLoS ONE, Vol 15, Iss 7, p e0236604 (2020) |
| ISSN: | 1932-6203 |
| Popis: | The clinical pipeline continues to be insufficient to contain antimicrobial resistance, and further investment and research is needed to ensure that a robust pipeline is built to treat the WHO priority pathogens list of antibiotic-resistant bacteria. To shed light further upstream on the preclinical pipeline the WHO has undertaken a review of the antibacterial preclinical pipeline and published the data of all identified projects in a publicly accessible database. The database captures 252 unique antibacterial agents in preclinical development being developed by 145 individual institutions, of which the majority are smaller biotech companies and academic institutions. There is a higher degree of innovation in the preclinical pipeline with a significant number of non-traditional approaches being pursued. For even a fraction of these projects to reach clinical development or the market, there is a need to shift the market dynamics for new antibacterials through the identification of new solutions beyond push and pull incentives. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |